Neuroendocrine Tumors

Well Differentiated

1st Line

Operable

NET0030
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors
PI: Visser
Sponsor: Stanford University
1st Priority

NET0032
Phase III Peptide Receptor Radionuclide Tx w/ Lu-Edotate vs SoC in SSTR+ Neuroendocrine Tumors
PI: Igaru
Sponsor: ITM Solucin GmbH

Inoperable

ECOG-ACRIN A021602
Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus
PI: Shahgufta
Sponsor: ECOG-ACRIN

2nd Line

NET0033
Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Palisiptone Treatment in Carcinoid Syndrome
PI: Shaheen
Sponsor: Crinetics Pharmaceuticals, Inc.